EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with...
NEW YORK, NY and SOUTH SAN FRANCISCO, Calif – July 7, 2020 -- EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling...
EVQLV is excited to announce we've joined the BAJ Accelerator. The accelerator runs from Monday, May 18th to Friday, May 22nd. We're confident BAJ will provide the necessary support and resources we need to reach the next level in our journey. About BAJ: BAJ...
For the unaware, we are collaborating with ImmunoPrecise to develop treatment for the coronavirus. We recently submitted our first panel of optimized antibody sequences. See below. EVQLV, has submitted their first panel of candidate therapeutic antibody sequences,...
Talem Therapeutics, a subsidiary of ImmunoPrecise, and EVQLV announced a new collaboration aimed at accelerating the global effort to develop lead therapeutic and vaccine candidates against the SARS-CoV-2 virus (coronavirus). EVQLV will perform in silico antibody...